C12N 2710/24071
Demonstrated in vivo effect
C12N2710/24071 (Demonstrated in vivo effect) appears on 22 US grants and 35 published applications in this corpus.
Search patents in C12N- Granted patents
- 22
- Published applications
- 35
- Assignees
- 20
- Inventors
- 57
- Latest grant
- 17 Jun 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 3 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 2 | 2 |
| 2012 | 0 | 0 |
| 2013 | 1 | 1 |
| 2014 | 1 | 1 |
| 2015 | 2 | 4 |
| 2016 | 2 | 4 |
| 2017 | 0 | 1 |
| 2018 | 4 | 3 |
| 2019 | 1 | 3 |
| 2020 | 3 | 3 |
| 2021 | 2 | 4 |
| 2022 | 1 | 1 |
| 2023 | 1 | 2 |
| 2024 | 0 | 0 |
| 2025 | 2 | 0 |
By publication year.
Recent patents
- Oncolytic virus platform to treat cancers with myxoma virus17 Jun 2025US 12,331,079 B2Arizona Board of Regents on behalf of Arizona State University
- Prostate neoantigens and their uses13 May 2025US 12,295,997 B2Janssen Biotech, Inc.
- Triple vaccine against avibacterium paragallinarum and avian encephalomyelitis virus and fowl pox virus3 Jan 2023US 11,541,115 B2
- Drug delivery system based on JCV-VLP5 Apr 2022US 11,291,735 B2Life Science Inkubator Betriebs GmbH & Co. KG
- Oncolytic virus platform to treat cancers with myxoma virus14 Sep 2021US 11,117,934 B2Arizona Board of Regents on behalf of Arizona State University
- Prostate Neoantigens And Their Uses2 Feb 2023US 2023/0029453 A1Janssen Biotech, Inc.
- New oncolytic virus platform to treat cancers with myxoma virus26 Jan 2023US 2023/0025706 A1Arizona Board of Regents of behalf of Arizona State University
- Oncolytic myxoma virus expressing fast p14 to treat hematological cancer24 Mar 2022US 2022/0088096 A1Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and
- A new oncolytic virus platform to treat cancers with myxoma virus21 Oct 2021US 2021/0324014 A1Arizona Board of Regents on behalf of Arizona State University
- Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of an Immune Checkpoint Inhibitor8 Jul 2021US 2021/0205429 A1Bavarian Nordic A/S
Most cited
By later US patents
- Method of inducing and/or enhancing an immune response to tumor antigens15US 8,017,590 B1Sanofi Pasteur Limited · 2011
- Feline vaccines against avian influenza4US 7,910,112 B2Merial Limited · 2011
- Oncolytic virus platform to treat cancers with myxoma virus3US 11,117,934 B2Arizona Board of Regents on behalf of Arizona State University · 2021
- Myxoma virus mutants for cancer treatment2US 8,512,713 B2Robarts Research Institute · 2013
- System for treating and preventing breast cancer2US 8,933,041 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2015